At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 20 enrolled
Drug / intervention
cinacalcet hydrochloride +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Trial to Assess the Effect of Cinacalcet Hydrochloride on PSA Levels in Patients With Biochemically Recurrent Prostate Cancer After Failed Definitive Local Therapy
In Brief
A Phase 2 clinical trial evaluating laboratory biomarker analysis, quality-of-life assessment, and 2 other interventions for Adenocarcinoma of the Prostate and Recurrent Prostate Cancer. Completed, enrolled 20 participants across 1 site.
Detailed Summary
This phase II trial is studying how well cinacalcet hydrochloride works in treating men with recurrent prostate cancer. Cinacalcet hydrochloride may be effective in lowering prostate-specific antigen (PSA) levels in patients with recurrent prostate cancer that has not responded to previous treatment
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI)
Timeline
Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedJan 2010
Enrollment StartSep 2011
Primary CompletionAug 2014
TodayJul 2026
First PostedJan 22, 2010
Enrollment StartSep 1, 2011
Primary CompletionAug 1, 2014
TodayJul 2, 2026
Enrollment to primary: 2.9 yearsPosted 16.4 years ago
Interventions
laboratory biomarker analysisother
Correlative study
quality-of-life assessmentprocedure
Ancillary study
questionnaire administrationother
Ancillary study
cinacalcet hydrochloridedrug
Given PO